Sign In
Buy ATRC
$25.86
-0.620 (-2.34%)
At Close: Jun 02, 2026
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
08:00am, Wednesday, 27'th May 2026
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure, Inc. (ATRC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
03:30pm, Tuesday, 12'th May 2026
AtriCure, Inc. (ATRC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook
03:10pm, Tuesday, 12'th May 2026
AtriCure NASDAQ: ATRC executives said the company's 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and expanding
AtriCure, Inc. (ATRC) Q1 2026 Earnings Call Transcript
02:11am, Wednesday, 06'th May 2026
AtriCure, Inc. (ATRC) Q1 2026 Earnings Call Transcript
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q1 Earnings
09:31pm, Tuesday, 05'th May 2026
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street
AtriCure (ATRC) Reports Break-Even Earnings for Q1
06:16pm, Tuesday, 05'th May 2026
AtriCure (ATRC) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.14 per share a year ago.
AtriCure Reports First Quarter 2026 Financial Results
04:01pm, Tuesday, 05'th May 2026
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op
AtriCure to Participate in the 2026 Bank of America Securities Health Care Conference
08:00am, Tuesday, 28'th Apr 2026
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
Riverwater Small Cap Strategy: Q1 2026 Buys, Sells, And Standouts
10:10pm, Sunday, 26'th Apr 2026
Modine Manufacturing led the way during the quarter, benefiting from secular demand in data center cooling and a well received spinoff of Modine Manufacturing's auto cooling business. Coming out of 20
AtriCure to Announce First Quarter 2026 Financial Results
08:00am, Tuesday, 14'th Apr 2026
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching?
04:06pm, Wednesday, 18'th Mar 2026
ArtiCure Chief Science Officer sold 5,000 shares for a transaction value of approximately $149,000 at around $29.83 per share on March 12, 2026. The sale represented 4.91% of Vinayak's direct holdings
AtriCure, Inc. (NASDAQ:ATRC) Receives Average Rating of “Moderate Buy” from Analysts
02:10am, Tuesday, 10'th Mar 2026
Shares of AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten analysts that are currently covering the company, Marketbeat.com reports. One an
Citigroup Inc. Purchases 36,839 Shares of AtriCure, Inc. $ATRC
03:36am, Monday, 09'th Mar 2026
Citigroup Inc. raised its position in AtriCure, Inc. (NASDAQ: ATRC) by 182.0% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (
AtriCure to Participate in the Citizens Life Sciences Conference
08:00am, Tuesday, 24'th Feb 2026
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure Q4 Earnings Call Highlights
04:06am, Thursday, 19'th Feb 2026
AtriCure (NASDAQ: ATRC) reported fourth-quarter and full-year 2025 results that management said reflected accelerating growth in several core franchises, improving profitability, and progress on major
